Skip to content

Amneal Pharmaceuticals, Inc.

AMRX

CIK 0001723128

← back to feed
Revenue (TTM)
$2.93B
+8.0% YoY Q1 Apr 2026
Net Income (TTM)
$99.24M
+161.6% YoY Q1 Apr 2026
EPS Diluted (TTM)
$0.31
+157.9% YoY Q1 Apr 2026
Gross Margin
38.8%
Q1 Apr 2026
Operating Margin
14.5%
Q1 Apr 2026
Net Margin
3.4%
Q1 Apr 2026
Free Cash Flow (TTM)
$75.74M
Q1 Apr 2026
Cash
$197.66M
Q1 Apr 2026
Total Debt
$2.57B
Q1 Apr 2026
Shares Outstanding
319.02M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings